What is Bioss?
Bioss operates as a critical infrastructure provider in the life sciences sector, specializing in the development and manufacturing of high-quality antibodies and related biological reagents. With a comprehensive catalog exceeding 18,000 primary and secondary antibodies, alongside specialized ELISA kits and recombinant proteins, the company serves as a foundational partner for researchers in immunology, oncology, and neuroscience. By maintaining a global distribution network and offering custom antibody solutions, Bioss facilitates essential discovery processes, positioning itself as a vital contributor to advancements in both human and animal health diagnostics.
How much funding has Bioss raised?
Bioss has raised a total of $345K across 2 funding rounds:
Debt
$150K
Debt
$195K
Debt (2020): $150K with participation from PPP
Debt (2021): $195K led by PPP
Key Investors in Bioss
PPP
Public-Private Partnership
What's next for Bioss?
With the recent infusion of capital, Bioss is well-positioned to scale its manufacturing capabilities and expand its portfolio of diagnostic tools. The company's strategic roadmap likely involves deepening its penetration into high-growth research markets and enhancing its recombinant protein production to meet the evolving demands of the global scientific community. As the firm transitions through this late-stage growth phase, the focus will remain on operational excellence and the continued diversification of its product offerings to maintain its competitive edge in the biotechnology supply chain.
See full Bioss company page
